Search:   [Advanced]

Search Results

Search for "Eplerenone" returned 16 results

Showing 1-16 out of 16

DrugBank ID	Name	Formula	Weight
DB00700	Eplerenone	C24H30O6	414.4914
	... increases the effect and toxicity of eplerenone Lithium Eplerenone increases serum levels of lithium Nefazodone Nefazodone increases the effect and toxicity of eplerenone Nelfinavir This ...
DB01344	Polystyrene sulfonate	C8H7CaO3S	223.2820
	... renal impairment Calcium Risk of alkalosis in renal impairment Eplerenone Risk of alkalosis in renal impairment Magnesium Risk of alkalosis in renal impairment Potassium Risk of alkalosis in ...
DB01345	Potassium	K	39.0983
	... risk of hyperkaliemia Enalapril Increased risk of hyperkaliemia Eplerenone This association presents an increased risk of hyperkaliemia Eprosartan Increased risk of hyperkaliemia Forasartan ...
DB00196	Fluconazole	C13H12F2N6O	306.2708
	... Possible ergotism and severe ischemia with this combination Eplerenone This CYP3A4 inhibitor increases the effect and toxicity of eplerenone Ergotamine Possible ergotism and severe ischemia ...
DB01149	Nefazodone	C25H32ClN5O2	470.0070
	... Eplerenone Nefazodone increases the effect and toxicity of eplerenone Ergotamine Possible ergotism and severe ischemia with this combination Erlotinib This CYP3A4 inhibitor increases levels ...
DB00384	Triamterene	C12H11N7	253.2626
	... risk of hyperkaliemia Enalapril Increased risk of hyperkaliemia Eplerenone This association presents an increased risk of hyperkaliemia Eprosartan Increased risk of hyperkaliemia Forasartan ...
DB00594	Amiloride	C6H8ClN7O	229.6270
	... effect of quinidine Enalapril Increased risk of hyperkaliemia Eplerenone The association presents an ncreased risk of hyperkaliemia Eprosartan Increased risk of hyperkaliemia Forasartan ...
DB00220	Nelfinavir	C32H45N3O4S	567.7820
	... inhibitor increases the effect and toxicity of eletriptan Eplerenone The protease inhibitor increases the effect and toxicity of eplerenone Ergotamine Nelfinavir increases the effect and ...
DB01211	Clarithromycin	C38H69NO13	747.9534
	... Eplerenone This macrolide increases the effect and toxicity of eplerenone Ergotamine Risk of ergotism and severe ischemia with this association Erlotinib This CYP3A4 inhibitor increases levels ...
DB01356	Lithium	Li	6.9410
	... The ACE inhibitor increases serum levels of lithium Eplerenone Eplerenone increases serum levels of lithium Eprosartan The ARB increases serum levels of lithium Etoricoxib Etoricoxib increases ...
DB01026	Ketoconazole	C26H28Cl2N4O4	531.4310
	... inhibitor increases the effect and toxicity of the triptan Eplerenone The imidazole increases the effect and toxicity of eplerenone Ergotamine Possible ergotism and sever ischemia with this ...
DB00199	Erythromycin	C37H67NO13	733.9268
	... The macrolide increases the effect and toxicity of eletriptan Eplerenone This CYP3A4 inhibitor increases the effect and toxicity of eplerenone Ergonovine Possible ergotism and severe ischemia ...
DB01167	Itraconazole	C35H38Cl2N8O4	705.6330
	... Eplerenone The imidazole increases the effect and toxicity of eplerenone Ergotamine Possible ergotism and severe ischemia with this combination Erlotinib This potent CYP3A4 inhibitor increases ...
DB00976	Telithromycin	C43H65N5O10	812.0037
	... or monitor for changes in the therapeutic/adverse effects of Eplerenone if Telithromycin is initiated, discontinued or dose changed. Ergoloid mesylate Telithromycin may reduce clearance of ...
DB00519	Trandolapril	C24H34N2O5	430.5372
	Monitor Trandolapril efficacy. Eplerenone Increased risk of hyperkalemia. Monitor serum potassium levels. Epoprostenol The prostacyclin analogue, Epoprostenol, may increase the hypotensive effect ...
DB00374	Treprostinil	C23H34O5	390.5131
	Monitor for increased bleeding during concomitant thearpy. Eplerenone Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. Eprosartan Additive hypotensive effect.

Showing 1-16 out of 16

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.